Sotabase

Career

· Master of Science in Robotics and Automation, Universidad Carlos III de Madrid2013–2015
· Ph.D. in Mechatronics, Robotics, and Automation Engineering, Universidad Carlos III de Madrid2013–2015
· Research Assistant, Universidad Carlos III de Madrid2011–2015
· Sr. Software Engineer, Magic Leap
· Computer Vision Engineer, Meta
· Robot Navigation Engineer, Rapyuta Robotics
· Ph.D. Candidate / Researcher, Stanford University

Publications (34)

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Journal of Clinical Oncology · 2009
506
cited
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
The Lancet Oncology · 2020
337
cited
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
The Lancet Respiratory Medicine · 2022
84
cited
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer
BMC Cancer · 2014
74
cited
An asymptotically-optimal sampling-based algorithm for Bi-directional motion planning
IEEE/RJS International Conference on Intelligent RObots and Systems · 2015
50
cited
Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
Journal of Clinical Pathology · 2021
39
cited
Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors
Clinical Cancer Research · 2008
39
cited
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
Life Science Alliance · 2022
38
cited
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
Cancer Chemotherapy and Pharmacology · 2012
27
cited
Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
Clinical Cancer Research · 2009
26
cited
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
Gynecologic Oncology · 2011
25
cited
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
Cancer Chemotherapy and Pharmacology · 2011
25
cited
Anti-perlecan antibodies and acute humoral rejection in hypersensitized patients without forbidden HLA specificities after kidney transplantation.
Transplant Immunology · 2019
19
cited
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials
Medical Oncology · 2013
17
cited
Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.
Clinical colorectal cancer · 2007
13
cited
Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule
2001
11
cited
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.
medRxiv · 2021
10
cited
Improvement in the definition of anti-HLA antibody profile in highly sensitized patients
PLoS ONE · 2017
9
cited
7500 ORAL Impact of independent review on efficacy outcomes in a randomised multicenter trial of trabectedin given by two dosing regimens in patients (pts) with progressing leiomyosarcomas or liposarcomas (L-sarcomas)
2007
3
cited
8064 Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer
2009
3
cited
Sotabase